AUPH News and Press, Aurinia Pharmaceuticals Inc From 02/25/20

- Industry veteran, Max Colao, appointed Chief Commercial Officer - - Recruited four seasoned executives with expertise across critical commercial functions - - Rapidly preparing for the potential commercialization of voclosporin during the first half of 2021 - Aurinia Pharm...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “ Company ”) today announced that Mr. Peter Greenleaf, President and Chief Executive Officer, will present a corporate overview at the 9 th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2019 at...

"Don't be afraid of buying on a war scare." - Phillip Fisher A common theme in bioscience investing is that a stock tends to rally vigorously following a strong data release. Thereafter, it can either appreciate further, trade sideways or recede southbound. As such, you need to determine...

Innovation knows no borders allowing adventurous biotech investors the opportunity to find hidden gems located outside the major research and development hubs in the U.S., Europe, and Japan. One doesn't even need to look too far. Here we preview three such companies hailing from Canada, sp...

Biotech investors are always looking for ways to reduce risk. One method is to focus on stocks with drugs that have come out of phase 3 trials with good news. With enough research, you can usually figure out the odds of approval from the Food and Drug Administration (FDA), and how large the mark...

Healthcare Pulse The market doesn't like uncertainty. And when you think about healthcare, that uncertainty is immediately magnified. Fundamentally, healthcare couldn't be better positioned, with an aging America, rapidly advancing therapies, a faster-moving FDA, easy access to risk capi...

Aurinia Pharmaceuticals (NASDAQ: AUPH) has a big year ahead. The Canadian biopharmaceutical company plans on submitting a New Drug Application for what could become its first marketed drug to the U.S. Food and Drug Administration, and it expects to report data on its phase 2/3 trial for what...

Source: GraycellAdvisors.com Systematic Investing Systematic investing has become a growing part of the stock market. The investing style refers to a rules-based algorithmic system that limits or eliminates individual judgments and biases towards portfolio selection and adjustments. ...

Oyster Point Pharma ( OYST +4.6% ) is up on average volume in response to positive topline results from a Phase 2 clinical trial, MYSTIC , evaluating lead candidate OC-01 nasal spray for the treatment of dry eye disease. More news on: Oyster Point Pharma, Inc., Kala Pharmaceuticals,...

Aerie Pharmaceuticals (NASDAQ: AERI ) initiated with Neutral rating and $27 (6% upside) price target at Bank of America. More news on: Aurinia Pharmaceuticals Inc., BeyondSpring Inc., Cerecor Inc., Healthcare stocks news, Stocks on the move, , Read more ...